Mainz Biomed N.V. (MYNZ)

Market Cap	11.49M
Revenue (ttm)	917,203
Net Income (ttm)	-22.51M
Shares Out	2.00M
EPS (ttm)	-44.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215,111
Open	5.63
Previous Close	5.60
Day's Range	5.45 - 5.94
52-Week Range	0.18 - 8.20
Beta	0.32
Analysts	Buy
Price Target	14.00 (+143.9%)
Earnings Date	Apr 15, 2025

About MYNZ

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 5, 2021
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: MYNZ
• Website: https://mainzbiomed.com

Financial Performance

In 2023, Mainz Biomed's revenue was $895,479, an increase of 69.00% compared to the previous year's $529,877. Losses were -$26.30 million, -0.35% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for MYNZ stock is "Buy." The 12-month stock price forecast is $14.0, which is an increase of 143.90% from the latest price.

Price Target

$14.0

(143.90% upside)

Analyst Consensus: Buy